Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

568.55INR
26 May 2017
Change (% chg)

Rs-23.25 (-3.93%)
Prev Close
Rs591.80
Open
Rs592.00
Day's High
Rs598.45
Day's Low
Rs564.90
Volume
1,248,995
Avg. Vol
365,523
52-wk High
Rs854.50
52-wk Low
Rs564.90

Latest Key Developments (Source: Significant Developments)

Sun Pharma may have single digit decline in consol revenue for FY 18 vs FY 17 - exec
Friday, 26 May 2017 09:07am EDT 

May 26 (Reuters) - Sun Pharmaceutical Industries Ltd :Dilip Shanghvi says may have single digit decline in consol revenue for FY 18 versus FY 17.Dilip Shanghvi says "FY18 is likely to be a challenging year for us".Dilip Shanghvi says co took $45 million u.s. Inventory related charge in Q4 that is unlikely to be recurring.Dilip Shanghvi says co awaiting FDA inspection on Halol, unaware of FDA’s stance on the facility.Dilip Shanghvi says value of first-to-file products even during exclusivity is likely to go down.  Full Article

India's Sun Pharmaceutical Industries March-qtr consol profit down about 14 pct
Friday, 26 May 2017 07:16am EDT 

May 26 (Reuters) - Sun Pharmaceutical Industries Ltd :March quarter consol net profit 12.24 billion rupees.Consensus forecast for March quarter consol profit was 14.95 billion rupees.March quarter consol total revenue from operations 71.37 billion rupees.Consol net profit in March quarter last year was 14.16 billion rupees as per Ind-AS; consol total revenue from operations was 76.54 billion rupees.Recommended dividend of 3.50 rupees per share.Says reappointment of Dilip Shanghvi as MD.Says resignation of Uday Baldota as CFO.  Full Article

Sun Pharma announces fda filing acceptance of Biologics License Application for tildrakizumab
Wednesday, 24 May 2017 08:03am EDT 

May 24 (Reuters) - Sun Pharmaceutical Industries Ltd : :Sun Pharma announces U.S. FDA filing acceptance of Biologics License Application (bla) for tildrakizumab.  Full Article

Sun Pharma says US FDA files acceptance of BLA for Tildrakizumab
Wednesday, 24 May 2017 12:55am EDT 

May 24 (Reuters) - Sun Pharmaceutical Industries Ltd :Says US FDA filing acceptance of biologics license application (BLA) for Tildrakizumab.Says Tildrakizumab is investigational IL-23P19 inhibitor evaluated for treatment of moderate-to-severe plaque psoriasis..  Full Article

Beijing Science Sun Pharmaceutical to pay div of 2.5 yuan/10 shares for 2016
Tuesday, 25 Apr 2017 10:47pm EDT 

April 26(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:* Says it will pay dividend of 2.5 yuan/10 shares for 2016.  Full Article

Hunan China Sun Pharma Machinery unit signs partnership framework agreement on gene detection project
Thursday, 20 Apr 2017 10:08pm EDT 

April 21(Reuters) - Hunan China Sun Pharma Machinery Co Ltd <300216.SZ> ::* Says its unit signed a partnership framework agreement with Changsha county local health bureau, to provide service for gene detection project for hypertensive patients .  Full Article

Hunan China Sun Pharma Machinery to pay annual cash div as 0.6 yuan per 10 shares for FY 2016
Wednesday, 19 Apr 2017 02:42am EDT 

April 19(Reuters) - Hunan China Sun Pharma Machinery Co Ltd <300216.SZ> : :* Says it plans to pay annual cash dividend as 0.6 yuan(pre-tax) per 10 shares as FY 2016 div payment.  Full Article

Hunan China Sun Pharma Machinery sees Q1 FY 2017 net profit up 0 to 30 pct
Tuesday, 11 Apr 2017 01:30am EDT 

Hunan China Sun Pharma Machinery Co Ltd <300216.SZ> : Sees Q1 FY 2017 net profit to increase by 0 to 30 percent, or to be 18.6 million yuan to 24.2 million yuan . Says Q1 FY 2016 net profit was 18.6 million yuan .The reason for the forecast is increased income of intelligent hybrid packing automatic production line.  Full Article

Beijing Science Sun Pharmaceutical sees FY 2017 Q1 net profit to decrease by 5 pct to 25 pct
Monday, 10 Apr 2017 02:30am EDT 

Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ> : Sees net profit for FY 2017 Q1 to decrease by 5 percent to 25 percent, or to be 44.1 million yuan to 61.8 million yuan, compared to net profit of FY 2016 Q1 (58.9 million yuan) .Says industry circulation policy as main reason for the forecast.  Full Article

Almirall says regulatory filing for Tildrakizumab in Europe is validated
Friday, 24 Mar 2017 02:57am EDT 

Almirall SA :The company and Sun Pharma announce validation of regulatory filing for Tildrakizumab, an antibody designed for treatment of moderate-to-severe plaque psoriasis, by the European Medicines Agency (EMA).  Full Article

More From Around the Web